AN2 Therapeutics, Inc.

NASDAQ:ANTX

Biotechnology

Healthcare
$5.22 +0.82%

+$0.04 today

Market cap
$198.07M
Beta
-0.98
P/E (TTM)
-4.9
EPS (TTM)
-$1.01
52W Low $1.00High $6.91

Volume 0.79M

Average 0.29M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$29.83M

FY 2025 · Annual

Investing Cash Flow

$28.31M

FY 2025 · Annual

-48.1% YoY

Financing Cash Flow

$113,000.00

FY 2025 · Annual

-69.6% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(21.54M)(40.96M)(64.73M)(51.32M)(35.17M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation974K4.39M8.41M8.34M6.25M
Change in Working Capital32K3.72M5.83M(3M)164K
Accounts Receivables00000
Inventory00000
Accounts Payables417K2.5M553K641K(296K)
Other Working Capital(385K)1.22M5.28M(3.64M)460K
Other Non-Cash Items53K(615K)(2.8M)(3.28M)(1.07M)
Operating Cash Flow(20.48M)(33.46M)(53.29M)(49.26M)(29.83M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments(77.27M)(93.84M)(132.18M)(46.75M)(46.19M)
Sales of Investments27.25M72.07M88.9M101.34M74.5M
Other Investing Activities00000
Investing Cash Flow(50.02M)(21.77M)(43.28M)54.59M28.31M
Debt Repayment00000
Common Stock Issued070.37M84.53M372K113K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.2M)(11K)465K00
Financing Cash Flow78.54M70.36M84.99M372K113K
Effect of Forex Changes00000
Net Change in Cash8.03M15.12M(11.57M)5.7M(1.41M)
Free Cash Flow(20.48M)(33.46M)(53.29M)(49.26M)(29.83M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$35.2M
+ D&A$0
+ Stock-Based Comp$6.2M
+ Deferred Tax$0
+ Working Capital$164.0K
- Other Non-Cash-$1.1M
= Operating Cash Flow-$29.8M
- Capex$0
= Free Cash Flow-$29.8M

Analysis

FY2025 free cash flow is -$29.8M. FCF conversion is 84.8% of net income. Operating cash flow was -$29.8M, with capex of $0. The largest bridge item is Stock-Based Comp at $6.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
SC 13G/ASC 13G/A filingNov 13, 2026
SC 13G/ASC 13G/A filingNov 13, 2026
8-KCurrent reportNov 9, 2026
10-QQuarterly reportNov 9, 2026
4Statement of changes in beneficial ownershipNov 6, 2026

Does ANTX generate free cash flow?

AN2 Therapeutics, Inc. (ANTX) generated -$29.83M of free cash flow in fiscal 2025.

How much operating cash flow does ANTX produce?

Operating cash flow was -$29.83M, before capital expenditures of $0.00.